



Natco Pharma Limited
Regd. Off. : 'NATCO HOUSE', Road No. 2, Banjara Hills, Hyderabad - 500034.
Telangana, INDIA. Tel : +91 40 23547532, Fax : +91 40 23548243
CIN : L24230TG1981PLC003201, www.natcopharma.co.in

October 9, 2025

Corporate Relationship Department
BSE Ltd.
Mumbai 400 001

Manager – Listing
National Stock Exchange of India Ltd
Mumbai 400 051

Scrip Code: **524816**

Scrip Code: **NATCOPHARM**

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

With reference to the above cited subject, please find enclosed herewith the Press Release under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015,

This is for your information.

Thanking you,

Yours faithfully
For NATCO Pharma Limited

Ch. Venkat Ramesh
Company Secretary &
Compliance Officer

NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

Legal update regarding**Risdiplam – Commercial Appellate Division of the Hon'ble Delhi High Court Dismissed Appeal**

Hyderabad, India, October 09th, 2025: NATCO Pharma Limited (BSE: 524816 and NSE: NATCOPHARM) ("NATCO") today updates on the legal proceedings on Risdiplam launch in India

With reference to earlier update on 8th April 2025, the Ld. Single Judge of Delhi High Court had through order dated 24.03.2025 denied Roche's plea for an injunction against the Company for the drug. Roche's appeal before the appellate Bench Delhi Court was announced today dated 9th October 2025 as appeal refused and consequently the status quo has been removed.

Today, in a landmark decision, the Commercial Appellate Division of the Hon'ble Delhi High Court, dismissed an appeal filed by the Swiss Pharmaceutical Company F. Hoffmann-La Roche AG.

With arguments spanning over several months, a Ld. Single Judge of the Hon'ble Delhi High Court, in groundbreaking judgment dated 24.03.2025, paved the way for NATCO to launch a generic version of the drug 'Risdiplam' which is used for treatment of the debilitating disease Spinal Muscular Atrophy (SMA). SMA is one of the leading causes of death in infants related to the degeneration of neurons. Currently, there are no curative treatment options for SMA, and most of the available options are not financially feasible for Indian patients. The Ld. Single Judge had factored the challenge of invalidity of Roche's patent and laid special emphasis on the public interest, considering the Swiss Company's pricing had rendered the drug inaccessible and unaffordable to the bulk of its patients.

The Appeal was preferred against the said order of the Ld. Single Judge. In a first of its kind, in dismissing the appeal, the Division Bench has removed the final hurdle in allowing a lifesaving drug like Risdiplam to be accessible at an affordable price to the Indian patients. This ruling would bring some hope to the countless lives that have been debilitated by an ailment like Spinal Muscular Atrophy (SMA).

The Company has decided to launch the product with immediate effect and price the product at INR 15,900 MRP consistent with the Company's stand before the court. The Company also intends to offer some discount to certain deserving patients through its patient access programme.

About NATCO Pharma Limited

NATCO Pharma Limited, (NSE:NATCOPHARM, BSE: 524816, Reuters: NATP.NS, Bloomberg: NTCPH,) headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company's differentiated manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets. For more information, please visit us at www.natcopharma.com.



NATCO Pharma Ltd

Natco House
Road No.2, Banjara Hills
Hyderabad-500 034, India

For further information or queries please contact:

Rajeev Menon – Manager, Investor Relations
Email: ir@natcopharma.co.in

Rajesh Chebiyam – EVP, Crop Health Sciences
Email: investors@natcopharma.co.in

Tel: 040-23547532 / Ext – 323

Follow us on:

X (formerly Twitter): https://twitter.com/pharma_natco

LinkedIn: <https://www.linkedin.com/company/natcopharma>